본문 바로가기
KERD
논문KCI 등재

정신약물에 의한 피부 부작용

Cutaneous Adverse Reaction of Psychotropic Agents

이승재|김병수|장성만|우정민|원승희|임효덕
대한생물치료정신의학회 (Korean Society Of Biological Therapies In Psychiatry)|2017.10|생물치료정신의학 (Journal of the Korean Society of Biological Therapies in Psychiatry)|제23권 제3호|pp. 121-126|DOI 10.22802/jksbtp.2017.23.3.121

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

정신약물·피부 부작용.Psychotropic agent · Cutaneous adverse reaction.
주제분류정신과학

초록

Psychotropic drugs are one of the most widely prescribed drugs. Adverse skin reactions are associated with psychotic drugs. These drug side effects occur in about 2% to 5% of patients. Mostly, the prognosis is good. However, some may be life-threatening. Life-threatening side effects are mainly related to mood stabilizers, antidepressants, and antipsychotic drugs. Once these side effects occur, the drug should be discontinued and treated for cutaneous and related symptoms. However, it would be better if prevention could be done before these side effects develop. Interestingly, mild adverse events occur within a few days, and severe adverse events develop after 1-3 weeks. Regardless of its severity, skin adverse effects can cause secondary issues that increase the cost of treatment and lower the patient's adherence to medications, so clinician should be able to recognize and respond quickly to this problem.

Abstract

Psychotropic drugs are one of the most widely prescribed drugs. Adverse skin reactions are associated with psychotic drugs. These drug side effects occur in about 2% to 5% of patients. Mostly, the prognosis is good. However, some may be life-threatening. Life-threatening side effects are mainly related to mood stabilizers, antidepressants, and antipsychotic drugs. Once these side effects occur, the drug should be discontinued and treated for cutaneous and related symptoms. However, it would be better if prevention could be done before these side effects develop. Interestingly, mild adverse events occur within a few days, and severe adverse events develop after 1-3 weeks. Regardless of its severity, skin adverse effects can cause secondary issues that increase the cost of treatment and lower the patient's adherence to medications, so clinician should be able to recognize and respond quickly to this problem.

참고문헌 (54)

  1. Bliss SA, "Psychiatric medications: adverse cutaneous drug reactions", Clin Dermatol, 31, pp.101~109 (2013)
  2. Valeyrie-Allanore L, "Drug-induced skin, nail and hair disorders", Drug Saf, 30, pp.1011~1030 (2007)
  3. Kimyai-Asadi A, "Critical overview:adverse cutaneous reactions to psychotropic medications", J Clin Psychiatry, 60, pp.714~725 (1999)
  4. Borroni RG, "Pharmacogenetic markers of severe cutaneous adverse drug reactions", G Ital Dermatol Venereol, 149, pp.219~226 (2014)
  5. Rzany B, "Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany(1990-1992):structure and results of a population-based registry", J Clin Epidemiol, 49, pp.769~773 (1996)
  6. Bastuji-Garin S, "SCORTEN: a severity-ofillness score for toxic epidermal necrolysis", J Invest Dermatol, 115, pp.149~153 (2000)
  7. Carneiro SC, "Drug eruptions in the elderly", Clin Dermatol, 29, pp.43~48 (2011)
  8. Svensson CK, "Cutaneous drug reactions", Pharmacol Rev, 53, pp.357~379 (2001)
  9. Mitkov MV, "Dermatologic side effects of psychotropic medications", Psychosomatics, 55, pp.1~20 (2014)
  10. Srebrnik A, "Adverse cutaneous reactions to psychotropic drugs", Acta Derm Venereol Suppl (Stockh), 158, pp.1~12 (1991)
  11. Thami GP, "Delayed reactivation of haloperidol induced photosensitive dermatitis by methotrexate", Postgrad Med J, 78, pp.116~117 (2002)
  12. Lee AY, "A case of leukocytoclastic vasculitis associated with haloperidol", Clin Exp Dermatol, 24, pp.430~ (1999)
  13. AlMadhyan AB, "Angioedema associated with haloperidol", Int J Health Sci(Qassim), 9, pp.76~78 (2015)
  14. Kubota T, "Alopecia areata associated with haloperidol", Jpn J Psychiatry Neurol, 48, pp.579~581 (1994)
  15. Bhattacharya A, "Alopecia areata associated with haloperidol decanoate long-acting injection", Aust N Z J Psychiatry, 46, pp.69~ (2012)
  16. Monteagudo-Paz A, "Pulpitis as clinical presentation of photoallergic contact dermatitis due to chlorpromazine", Allergy, 66, pp.1503~1504 (2011)
  17. Greiner AC, "Skin Pigmentation and Corneal and Lens Opacities with Prolonged Chlorpromazine Therapy", Can Med Assoc J, 90, pp.663~665 (1964)
  18. Niczyporuk W, "Preliminary study on the effect of the selected calmodulin antagonists on the skin", Rocz Akad Med Bialymst, 41, pp.515~524 (1996)
  19. Burrows NP, "Pustular eruptions after chlorpromazine", BMJ, 309, pp.97~ (1994)
  20. Solfanelli A, "Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis", J Child Adolesc Psychopharmacol, 23, pp.232~234 (2013)
  21. Adams BB, "Pustular eruption induced by olanzapine, a novel antipsychotic agent", J Am Acad Dermatol, 41, pp.851~853 (1999)
  22. Jhirwal OP, "Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent", Int J Dermatol, 43, pp.778~779 (2004)
  23. Singh LK, "Olanzapine-Induced Reversible Pellagroid Skin Lesion", Curr Drug Saf, 10, pp.251~253 (2015)
  24. Molina-Ruiz AM, "Olanzapine-induced eccrine squamous syringometaplasia", Am J Dermatopathol, 34, pp.434~437 (2012)
  25. Gregoriou S, "Photo-onycholysis caused by olanzapine and aripiprazole", J Clin Psychopharmacol, 28, pp.219~220 (2008)
  26. Raz A, "A case report of olanzapine-induced hypersensitivity syndrome", Am J Med Sci, 321, pp.156~158 (2001)
  27. Parker C, "Aripiprazole induced severe and extensive skin reaction: A case report", Ther Adv Psychopharmacol, 2, pp.195~198 (2012)
  28. Shen YC, "Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?", Int Clin Psychopharmacol, 22, pp.247~248 (2007)
  29. Fong SY, "Clozapineinduced toxic hepatitis with skin rash", J Psychopharmacol, 19, pp.107~ (2005)
  30. Lai YW, "Pityriasis rosealike eruption associated with clozapine: a case report", Gen Hosp Psychiatry, 34, pp.703~ (2012)
  31. Bhatti MA, "Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash", J Clin Psychiatry, 66, pp.1490~1491 (2005)
  32. Hauben M, "Comment: papular rash and bilateral pleural effusion associated with clozapine", Ann Pharmacother, 33, pp.1374~ (1999)
  33. Stanislav SW, "Papular rash and bilateral pleural effusion associated with clozapine", Ann Pharmacother, 33, pp.1008~1009 (1999)
  34. Mishra B, "Risperidone-induced recurrent giant urticaria", Br J Clin Pharmacol, 64, pp.558~559 (2007)
  35. Burke GV, "Self-limited erythema multiforme with risperidone", Gen Hosp Psychiatry, 31, pp.295~296 (2009)
  36. Desarkar P, "Risperidone-induced erythema multiforme minor", Br J Clin Pharmacol, 62, pp.504~505 (2006)
  37. Lange-Asschenfeldt C, "Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program", J Clin Psychiatry, 70, pp.1258~1265 (2009)
  38. Jafferany M, "Lithium and skin: dermatologic manifestations of lithium therapy", Int J Dermatol, 47, pp.1101~1111 (2008)
  39. Chan HH, "A control study of the cutaneous side effects of chronic lithium therapy", J Affect Disord, 57, pp.107~113 (2000)
  40. O’Brien M, "The mechanism of lithium and betablocking agents in inducing and exacerbating psoriasis", J Drugs Dermatol, 5, pp.426~432 (2006)
  41. McCreadie RG, "The impact of lithium in South-west Scotland. I. Demographic and clinical findings", Br J Psychiatry, 146, pp.70~74 (1985)
  42. Kuhnley EJ, "Exfoliative dermatitis during lithium treatment", Am J Psychiatry, 136, pp.1340~1341 (1979)
  43. Gau SS, "The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study", J Clin Psychopharmacol, 28, pp.509~517 (2008)
  44. Yang CY, "Severe cutaneous adverse reactions to antiepileptic drugs in Asians", Neurology, 77, pp.2025~2033 (2011)
  45. Culy CR, "Lamotrigine. A review of its use in childhood epilepsy", Paediatr Drugs, 2, pp.299~330 (2000)
  46. Guberman AH, "Lamotrigine-associated rash: risk", benefit considerations in adults and children, 1999, pp.40, 985~991
  47. Schaub N, "Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro", Allergy, 55, pp.191~193 (2000)
  48. Warnock JK, "Adverse cutaneous reactions to antipsychotics", Am J Clin Dermatol, 3, pp.629~636 (2002)
  49. Preskorn SH, "Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine", J Clin Psychiatry, 56(Suppl 6), pp.12~21 (1995)
  50. Hedenmalm K, "Alopecia associated with treatment with selective serotonin reuptake inhibitors(SSRIs)", Pharmacoepidemiol Drug Saf, 15, pp.719~725 (2006)
  51. Beasley CM Jr, "Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis", Clin Ther, 22, pp.1319~1330 (2000)
  52. Edwards JG, "Adverse effects of antianxiety drugs", Drugs, 22, pp.495~514 (1981)
  53. Loncar C, "Toxic epidermal necrolysis caused by flurazepam?", Psychiatr Danub, 17, pp.236~239 (2005)
  54. Nigen S, "Drug eruptions: approaching the diagnosis of drug-induced skin diseases", J Drugs Dermatol, 2, pp.278~299 (2003)

관련 논문AI추천

정신과 약물에 의한 피부 부작용이지민, 장성만대한생물치료정신의학회 · 생물치료정신의학2025 · 제31권 제3호Chlorpromazine-induced Exfoliative Photoallergic Reaction김영훈, 이광복대한생물치료정신의학회 · 생물치료정신의학2020 · 제26권 제3호Lamotrigine과 Aripiprazole을 투여한 환자에서 발생한 과민성 반응 1예강웅구, 노재우, 박혜진대한신경정신의학회 · 신경정신의학2006 · 제45권 제4호약물유해반응 이후 처방의 변경 유형과 치료 결과: Lamotrigine 관련 사례 분석강정은, 서동인, 서비취, 서성연, 이경훈, 임정미, 조윤숙대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2023 · 제11권 제2호Quetiapine Fumarate의 제형 변경후 발생한 피부 발진 1예권용석, 임세원대한생물정신의학회 · 생물정신의학2009 · 제16권 제4호Causality Assessment of Cutaneous Adverse Drug Reactions노주영, 이종록, Young-Min Son대한피부과학회 · Annals of Dermatology2011 · 제23권 제4호

이 간행물의 다른 논문 (13건)

밈 이론의 관점에서 본 정신 질환의 이해주연우, 이승복, 손정우pp. 127-137운동이 기분 및 우울증에 미치는 영향 및 임상적 적용 : 신경가소성의 관점에서민유선, 김병수pp. 138-146인지기능장애가 있는 지역사회 거주노인에서 삶의 질의 관련인자김성완, 김남준, 신일선, 김재민, 윤진상, 신희영pp. 147-154양극성 장애, 조증 삽화 입원 환자에서 조증 증상 경과 예측과 관련있는 임상 변인 연구박진완, 한상우, 이연정, 백두현, 우성일, 황재욱, 김채리pp. 155-163독거 노인의 삶의 질에 영향을 주는 요인이종훈, 정성일, 김재준, 윤서영, 김준원, 최태영, 김정은pp. 164-170
원문 보기